Funding for this research was provided by:
Medical Research Foundation (MR/P025404/1)
Eck Institute for Global Health, University of Notre Dame
Text and Data Mining valid from 2018-10-15
Received: 8 May 2018
Accepted: 5 September 2018
First Online: 15 October 2018
Ethics approval and consent to participate
: The study was approved by the Kenya Medical Research Institute/ Scientific and Ethics Review Unit (KEMRI/SERU), number 2776 and by CDC through a reliance agreement with KEMRI/SERU (CDC IRB 6728). Individuals participating in HLC gave a written consent. They were screened for malaria and treated if positive. The collectors were placed on malaria prophylaxis, Mephaquin (Acino Pharma AG, Switzerland) one week before collections begun, with repeat doses once every week through the collection period, until four weeks after collections ended. The household head for the compounds used in the study provided consent for use of cows.
: Not applicable.
: The authors declare they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.